The importance of dual IL-17 (IL-17A and IL-17F) inhibition in the treatment of psoriasis

Abstract

IL-17A is a key mediator of chronic tissue inflammation and plays a central role in the pathophysiology of many immune-mediated inflammatory diseases including psoriasis. IL-17F shares structural homology and partially overlapping biological functions with IL-17A. Bimekizumab is a humanized monoclonal IgG1 antibody that efficiently and selectively neutralizes the biological functions of both IL-17A and IL-17F. Here, we summarize the relevance of the differences between IL-17A and IL-17F related to the pathogenesis of psoriasis, and the potential of dual IL-17 inhibition by bimekizumab in the treatment of the disease.